Qube Research & Technologies LTD Larimar Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$4.2 - $13.28 $374,194 - $1.18 Million	89,094 New	89,094 $676,000
Q1 2023 May 15, 2023	BUY	$4.0 - $6.68 $183,128 - $305,823	45,782 New	45,782 $207,000
Q2 2021 Aug 13, 2021	SELL	$8.0 - $15.2 $88,984 - $169,069	-11,123 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$14.61 - $22.19 $464,598 - $705,642	-31,800 Reduced 74.09%	11,123 $163,000
Q4 2020 Feb 16, 2021	BUY	$14.28 - $25.06 $75,369 - $132,266	5,278 Added 14.02%	42,923 $919,000

Q3 2020 Nov 12, 2020	BUY	$10.5 - $17.6 $395,272 - $662,552	37,645 New	37,645 $571,000

156

89M

6.44M

622K

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $146M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.